Author

Fanfan Li

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Iza-bren significantly improved progression-free survival versus chemotherapy, and median progression-free survival assessed by Blinded Independent Central Review was 8·2 months (95% CI 6·9-8·6) versus 4·0 months (2·9-4·3; HR 0·41 [95% CI 0·33-0·53).

B. Lan, Ye-Hui Shi, Xi-Ying Shao et al. · The Lancet · 0 citations

Review Sep 2026

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

PURPOSE To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/metastatic breast cancer (BC). METHODS In this phase III, open-label, multicenter trial (ClinicalTrials.gov...

Jian Zhang, Q. Ouyang, Qing-Yuan Zhang et al. · Journal of Clinical Oncology · 0 citations

Aug 2026

ARID1B mutations promote immune evasion in acute myeloid leukemia through upregulating VISTA expression.

Acute myeloid leukemia (AML) is defined by epigenetic heterogeneity, and recurrent mutations in chromatin remodelers are associated with a poor prognosis. Whether these mutations drive treatment resistance through remodeling of the tumor immune microenvironment remains unclear. ARID1B, a recurrently mutated SWI/SNF sub...

Wan-Xiu Mao, Jia-Yi Cui, Hanqi Su et al. · International Immunopharmaco... · 0 citations